Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
暂无分享,去创建一个
T. Matsuda | Tomoaki Tanaka | T. Imai | M. Yamada | K. Takekoshi | M. Nomura | F. Satoh | A. Ichihara | T. Okamoto | T. Katabami | M. Naruse | T. Harada | A. Tanabe | M. Tsuiki | Nobuyuki Kawata
[1] Edward H. Kennedy,et al. Preoperative Metyrosine Improves Cardiovascular Outcomes for Patients Undergoing Surgery for Pheochromocytoma and Paraganglioma , 2015, Annals of Surgical Oncology.
[2] W. Young,et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.
[3] S. Ito,et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. , 2014, Endocrine-related cancer.
[4] L. Brunton. Goodman & Gilman's The pharmacological basis of therapeutic , 2013 .
[5] Herb Chen,et al. The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer , 2010, Pancreas.
[6] Michael A Choti,et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[7] S. Targum,et al. The clinical global impressions scale: applying a research tool in clinical practice. , 2007, Psychiatry (Edgmont (Pa. : Township)).
[8] J. Norton,et al. High‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma , 2003, Cancer.
[9] J. Sisson. Radiopharmaceutical Treatment of Pheochromocytomas , 2002, Annals of the New York Academy of Sciences.
[10] B. Shapiro,et al. Radioisotope diagnosis and therapy of malignant pheochromocytoma , 2001, Trends in Endocrinology & Metabolism.
[11] Carr Aa,et al. Metyrosine and pheochromocytoma. , 1997, Archives of internal medicine.
[12] W. Travis,et al. Surgical Management of Pheochromocytoma with the Use of Metyrosine , 1991 .
[13] D. Edwards,et al. Alternative catecholamine pathways after tyrosine hydroxylase inhibition in malignant pheochromocytoma. , 1990, The Journal of laboratory and clinical medicine.
[14] E. Gelmann,et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. , 1988, Annals of internal medicine.
[15] A. P. Shapiro,et al. Pathogenesis and pharmacologic management of pseudo-obstruction of the bowel in pheochromocytoma. , 1985, The American journal of the medical sciences.
[16] C. Grushkin,et al. Childhood pheochromocytoma: treatment with alpha methyl tyrosine for resistant hypertension. , 1977, The Journal of pediatrics.
[17] J. Salway,et al. Phaeochromocytoma with myocarditis managed with alpha-methyl-p-tyrosine. , 1976, Postgraduate medical journal.
[18] A. Amery,et al. α-methyl-p-tyrosine in malignant pheochromocytoma , 1969, Pharmacologia Clinica.
[19] N. Jones,et al. α-METHYL-p-TYROSINE IN THE MANAGEMENT OF PHÆOCHROMOCYTOMA , 1968 .
[20] A. Sjoerdsma,et al. Biochemical and pharmacologic effects of α-methyltyrosine in man , 1968 .
[21] ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. , 2001, Journal of postgraduate medicine.
[22] S. R. Nash,et al. Dopamine receptors: from structure to function. , 1998, Physiological reviews.
[23] N. Jones,et al. Alpha-methyl-p-tyrosine in the management of phaeochromocytoma. , 1968, Lancet.
[24] E. Pitkänen,et al. Alpha-methyl-p-tyrosine in the symptomatic treatment of patients with malignant phaeochromocytoma. , 1968, Annales medicinae internae Fenniae.